_______________________________________ Hyperlipidemias and Atherosclerotic Cardiovascular Disease
AHA/ACC RECOMMENDATIONS FOR STATIN SAFETY AND MANAGEMENT OF STATIN-ASSOCIATED SIDE EFFECTS
In patients with nonsevere statin-associated side effects, reassess and rechallenge to achieve maximal LDL lowering by modified dosing regimen, alternate statin, or in combination with nonstatin therapy (Class I, based on moderate-quality evidence). In patients with increased diabetes risk or new-onset diabetes, continue statin therapy with added emphasis on adherence, net clinical benefit, and core principles of healthy lifestyle (Class I, based on moderate-quality evidence). In patients treated with statins, measure creatine kinase levels in individuals with severe SAMS and objective muscle weakness. Measure liver transaminases as well as total bilirubin and alkaline phosphatase (hepatic panel) if symptoms suggest hepatotoxicity (Class I, based on limited data). In patients at increased ASCVD risk with chronic, stable liver disease (including non-alcoholic fatty liver disease), when appropriately indicated, it is reasonable to use statins after obtaining baseline measurements and determining a schedule of monitoring and safety checks (Class I, based on moderate-quality evidence). In patients at increased ASCVD risk with severe SAMS or recurrent SAMS despite appropriate statin rechallenge, it is reasonable to use randomized controlled trial-proven nonstatin therapy that is likely to provide net clinical benefit (Class IIa, based on moderate-quality evidence). SAMS = statin-associated muscle symptoms. Source: [24] Table 6
The AHA/ACC recommend that a clinician-patient risk discussion be conducted prior to the initiation of statin therapy to review and weigh the risk reduction benefit against the potential for adverse effects, drug-drug interactions, and safety. Patients with statin-associated muscle symptoms should be evaluated for nonstatin causes and predisposing factors. When a statin is indicated, identify predisposing factors for statin- associated side effects (e.g., new-onset diabetes mellitus, muscle symptoms) prior to initiating statin therapy ( Table 6 ) [24]. Drug Interactions Statins have pharmacokinetic interactions with drugs that inhibit their metabolism and increase their bioavailability, such as CYP3A4 inhibitors (e.g., azole antifungals, erythromycin, protease inhibitors, amiodarone, grapefruit) and CYP2C9 inhibitors (e.g., NSAIDs, phenytoin, warfarin), as well as drugs that potentiate statins’ therapeutic and adverse effects (e.g., fibrates, niacin). These interactions increase statin toxicity [67; 128; 163]. Interaction between statins and fibrates, particularly with gemfibrozil, increases the risk of rhabdomyolysis. For this reason, fenofibrate is preferred when the two classes are combined [140]. Clinical Outcome Statins, the most potent lipid-lowering drugs, are indicated in a variety of clinical conditions and are effective in the prevention of ASCVD and stroke. They lower LDL in a dose- dependent manner by 20% to 55% and are accepted as the drug of choice in the treatment of elevated LDL. They are also effective in the treatment of hypertriglyceridemias when levels are greater than 250 mg/dL, although fibrates remain the drug of choice for hypertriglyceridemias. When elevation of HDL is required, niacin remains the drug of choice, although
co-administration of statins and niacin may be considered in patients who also have an elevated LDL. Co-administration of statins and niacin, fibrates, or ezetimibe increases the lipid- lowering benefit but also increases the risk for adverse effects. Furthermore, randomized controlled trials do not support the use of fibrates and niacin as add-on drugs to statin therapy. However, if a fibrate is necessary in a patient being treated with a statin, it is safer to use fenofibrate than gemfibrozil due to lower risk of severe myopathy [24]. These patients should be carefully monitored. In patients taking statins who develop myopathy and creatine kinase levels 10 or more times higher than normal, immediate discontinuation of the drug is recommended. Dietary therapy and lifestyle changes should be implemented and other lipid-lowering drugs, such as niacin, fibrates, and bile-acid sequestrants, should be considered. The National Lipid Association Muscle Expert Panel guidelines recommend considering the re-introduction of low doses of statins in conjunction with ezetimibe in cases in which the lipid-lowering benefit of statins outweighs the risk of myopathy [140; 164].
The more LDL is reduced on statin therapy, the greater will be subsequent risk reduction. Therefore, the ACC/AHA recommend patients with clinical ASCVD be treated with a maximally tolerated statin to lower LDL levels by ≥50%.
(https://www.ahajournals.org/doi/pdf/10.1161/ CIR.0000000000000677. Last accessed July 24, 2025.) Level of Evidence : I (Strong)
42
MDAK1526
Powered by FlippingBook